content

CPhI China & P-MEC China Post Show Report 2019

CPhI & P-MEC China has become Asia’s largest and most specialised pharmaceutical event. Throughout the years, the event has witnessed the country’s pharmaceutical industry...

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market explored ahead of CPhI MEA

The rapid growth of Saudi Arabia’s pharmaceutical market will be placed under the spotlight at the forthcoming CPhI Middle East and Africa event, as...

Bora secures FDA approval for CDMO services

Bora, a contract development and manufacturing organization (CDMO) that specializes in modified release (MR) and solvent production, has reported a successful FDA general inspection...

Velesco Pharma set for clinical manufacturing capacity expansion

Pharmaceutical development and clinical manufacturing expert, Velesco Pharma, is set to triple its clinical manufacturing capacity with the purchase and fit-out of a new,...

The CPhI Annual Report: take part in pharma’s largest reputation survey

The global pharmaceutical landscape is evolving at an extraordinary pace as manufacturing capabilities, drug development technologies, and regulation advances creating new ways of innovating...

Tagrisso approved in China as a 1st line treatment for EGFR mutated non-small cell lung cancer

AstraZeneca announced that it has received marketing authorisation from China’s National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-line treatment for adults...

Thermo Fisher Scientific Announces Collaboration to Develop Advanced Analytical Workflows for Clinical Laboratories

Thermo Fisher Scientific, the world leader in serving science, and Cedars-Sinai, a leading nonprofit academic healthcare organization, have entered into a collaboration to develop...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read